65,437 trials
Gather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd Trimester
Primary: Difference in Fetal Heart Rate as Measured by VScan Access R2 and Corometrics — 4.2 Beats Per Minute (BPM)
Wounds
Primary: Wound Closure at Discharge — 100 percent of participants
Cancer
Primary: Proportion of Participants Initiating Treatment Within 90 Days of Diagnosis Among BREAST Cancer Participants — 94; 92 Participants — p=0.77
Adolescent Depression
Primary: CDRS-R Score — 34.94; 40.65 score on a scale
Major Depressive Disorder
Primary: Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12 — 57.8 percentage of participants
Antibody Mediated Rejection of Kidney Transplant
Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants
Ultrasound Guided Rectus Sheath Block · Pain, Postoperative
Primary: Immediate Postoperative Pain — 7.36; 1.04; 6.56 score on a scale
Graft Versus Host Disease
Primary: Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD. — 0 Participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Chronic Disease
Primary: New Advance Care Planning Documentation in the Medical Record at 15 Months — 83; 58 Participants
Appendicitis · Children
Primary: Decision Self-Efficacy Scale — 100; 100 units on a scale — p=0.03
Physical Activity · Acute Coronary Syndrome
Primary: Change in Mean Daily Steps — 264; 1501 Steps
Feeding Behavior
Primary: Differences in Food and Beverage Intake by Energy — 956; 884; 1041 kilocalories — p=< 0.0001
Healthy Adults
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 70066.90; 64711.53 pg*h/mL
Pharyngitis
Primary: Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First…